Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Clinical Pharmacology Study of the Effects of a Single 4 Hour Intravenous Infusion of Bendavia (MTP-131) in Subjects With Stable New York Heart Association Class II-III Congestive Heart Failure Due to Left Ventricular Systolic Dysfunction

Trial Profile

A Phase 1 Clinical Pharmacology Study of the Effects of a Single 4 Hour Intravenous Infusion of Bendavia (MTP-131) in Subjects With Stable New York Heart Association Class II-III Congestive Heart Failure Due to Left Ventricular Systolic Dysfunction

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Acronyms PREVIEW
  • Sponsors Stealth BioTherapeutics

Most Recent Events

  • 01 Dec 2017 Results published in the Circulation: Heart Failure
  • 16 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 26 May 2015 Positive results presented at the European Society of Cardiology (ESC) Heart Failure Congress 2015, according to a Stealth BioTherapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top